Sign inCreate account

Report workspace

Add to folder
NCT05261750ACTIVE_NOT_RECRUITINGanonymous

Safety and Efficacy of Adjuvant Therapy of Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer

Sponsor

Source record

PT. Prodia Stem Cell Indonesia

Phase

Source record

Phase 1/2

Modality

AI-normalized

protein therapy

Target

AI-normalized

Dendritic cells and dendritic secretomes as immunotherapeutic agents for advanced nasopharyngeal cancer.

Indication / condition

AI-normalized

Nasopharyngeal Cancer

Intervention

Source record

Placebo (Aqua Pro-Injection), Auto-DC (Autologous Dendritic Cell as Adjuvant Therapy), Combination of Auto DC and Allo-Dendritic Cell-Secretome (Allogeneic Dendritic Cell-Secretome as Adjuvant Therapy)

Source & freshness

Source record

NCT ID

NCT05261750

Original source

ClinicalTrials.gov

Source last updated

Feb 25, 2026

Ingested at

Jun 13, 2026

Internal sync

Jun 13, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT05261750

Title

Safety and Efficacy of Adjuvant Therapy of Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer

Sponsor

PT. Prodia Stem Cell Indonesia

Status

ACTIVE_NOT_RECRUITING

Phase

Phase 1/2

Condition raw

Nasopharyngeal Cancer

Condition normalized

Nasopharyngeal Cancer

Modality raw

protein therapy

Modality normalized

protein therapy

Target raw

Dendritic cells and dendritic secretomes as immunotherapeutic agents for advanced nasopharyngeal cancer.

Target normalized

Dendritic cells and dendritic secretomes as immunotherapeutic agents for advanced nasopharyngeal cancer.

Interventions

Placebo (Aqua Pro-Injection), Auto-DC (Autologous Dendritic Cell as Adjuvant Therapy), Combination of Auto DC and Allo-Dendritic Cell-Secretome (Allogeneic Dendritic Cell-Secretome as Adjuvant Therapy)

Public preview

Source record

The clinical trial, sponsored by PT. Prodia Stem Cell Indonesia, aims to evaluate the safety and efficacy of autologous dendritic cell therapy and allogenic dendritic secretomes in patients with advanced nasopharyngeal cancer. Given the rising incidence of nasopharyngeal cancer, particularly in Southeast Asia, this trial addresses a significant unmet medical need. If successful, the outcomes could position PT. Prodia as a leader in innovative cancer therapies within the region. However, the competitive landscape includes established immunotherapies and emerging therapies targeting similar pathways, necessitating thorough market analysis and strategic positioning. Diligence should focus on regulatory pathways and potential partnerships for commercialization.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Safety and Efficacy of Adjuvant Therapy of Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 16, 2026

NCT ID

NCT05261750

Status

ACTIVE_NOT_RECRUITING

Phase

Phase 1/2

Sponsor

PT. Prodia Stem Cell Indonesia

Executive brief

Investment-Ready Snapshot

The clinical trial, sponsored by PT. Prodia Stem Cell Indonesia, aims to evaluate the safety and efficacy of autologous dendritic cell therapy and allogenic dendritic secretomes in patients with advanced nasopharyngeal cancer. Given the rising incidence of nasopharyngeal cancer, particularly in Southeast Asia, this trial addresses a significant unmet medical need. If successful, the outcomes could position PT. Prodia as a leader in innovative cancer therapies within the region. However, the competitive landscape includes established immunotherapies and emerging therapies targeting similar pathways, necessitating thorough market analysis and strategic positioning. Diligence should focus on regulatory pathways and potential partnerships for commercialization.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedFeb 25, 2026
Internal syncJun 13, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT05261750

Indication

Nasopharyngeal Cancer

Modality

protein therapy

Target

Dendritic cells and dendritic secretomes as immunotherapeutic agents for advanced nasopharyngeal cancer.

Intervention

Placebo (Aqua Pro-Injection), Auto-DC (Autologous Dendritic Cell as Adjuvant Therapy), Combination of Auto DC and Allo-Dendritic Cell-Secretome (Allogeneic Dendritic Cell-Secretome as Adjuvant Therapy)

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.